Patients Show Strong Preference for New Subcutaneous Ocrelizumab Formulation: UVA Study

Originally published by our sister publication Specialty Pharmacy ContinuumBy Gina ShawOcrelizumab-hyaluronidase-ocsq (Ocrevus Zunovo, Genentech), the recently approved subcutaneous formulation of the multiple sclerosis (MS) drug ocrelizumab, is strongly preferred by patients over the standard ocrelizumab infusion, according to new data.Researchers from UVA Health implemented a pharmacy-led, clinic-based protocol for ocrelizumab-hyaluronidase-ocsq, which was approved by the FDA in September 2024